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Background: Signs and symptoms of the X-linked disorder, Fabry disease (FD), can occur early during childhood with
heterogeneous clinical manifestations including potential cardiac and renal dysfunction. Several studies support
the efficacy of the enzyme replacement therapy (ERT) agalsidase alfa, in adults with FD, though published data
on the long-term safety and efficacy of agalsidase alfa in children are limited. As early treatment with ERT has the
potential to reduce complications arising from disease progression, children in particular could benefit. The objective of
this study was to evaluate the safety and efficacy of long-term agalsidase alfa ERT in children with FD.
Methods: TKT029 was a 6.5-year open-label, multicenter, extension study of children who completed TKT023
(26-week, open-label, every-other-week, intravenous 0.2 mg/kg agalsidase alfa). TKT029 was divided into two
phases (before and after an agalsidase alfa manufacturing process change); only patients who participated in both
phases were included in the analysis. Primary endpoints included safety, tolerability, and heart rate variability
(HRV). Additional efficacy parameters included left ventricular mass index (LVMI), estimated glomerular filtration
rate (eGFR), and plasma/urine globotriaosylceramide (Gb3).
Results: Eleven patients participated (phase 1 baseline median [range] age: 10.8 [8.6–17.3] years; 10 [90.9%] males).
During TKT029 (6.5 years), all patients experienced ≥1 treatment-emergent adverse event (AE); eight patients had ≥1
possibly/probably drug-related AE. Six patients experienced infusion-related AEs, but none discontinued due to AEs.
Eight serious AEs arose (two patients); none were deemed drug-related. No deaths occurred. Three patients developed
anti-agalsidase alfa antibodies, with IgG antibodies in one patient that were agalsidase alfa neutralizing, but without
apparent clinical impact. Renal (eGFR) endpoints remained generally in normal range. Cardiac endpoints remained
stable within normal range for LVMI and a trend towards improved HRV, although some patients experienced a
reduction in heart rate. Plasma and urinary Gb3 reductions were maintained.
Conclusions: TKT029 represents the longest assessment of ERT in children with FD in a clinical trial setting. Overall,
agalsidase alfa was well tolerated and demonstrated a stabilizing clinical effect. Agalsidase alfa may be a useful clinical
therapeutic option for long-term treatment initiated during childhood in patients with FD.
Trial registration: http://ClinicalTrials.gov identifier NCT00084084.
Keywords: Enzyme replacement therapy, Lysosomal storage disorders, Safety and tolerability, Heart rate variability,
Estimated glomerular filtration rate* Correspondence: raphael.schiffmann@baylorhealth.edu
1Institute of Metabolic Disease, Baylor Research Institute, 3812 Elm Street,
Dallas, TX 75226, USA
Full list of author information is available at the end of the article
© 2014 Schiffmann et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Schiffmann et al. Orphanet Journal of Rare Diseases 2014, 9:169 Page 2 of 10
http://www.ojrd.com/content/9/1/169Background
The X-linked disorder Fabry disease (FD) is caused by
deficient activity of the glycolipid-degrading enzyme α-
galactosidase A, which leads to progressive accumula-
tion of the substrate globotriaosylceramide (Gb3) in
multiple body organs, resulting in potentially severe
and ultimately premature fatality [1]. Initial signs and
symptoms of FD are manifested during early childhood in
both sexes, but especially in affected boys, with symptoms
including angiokeratomas, neuropathic pain/acropar-
esthesia, hypohidrosis, gastrointestinal symptoms, cor-
nea verticillata, and less commonly, cardiac, renal, and
cerebrovascular involvement [2].
Enzyme replacement therapy (ERT) is available as a
treatment for patients with FD. However, the published
literature of ERT safety and efficacy in children with FD
is not as robust when compared with adults. Previously,
the clinical efficacy and safety of agalsidase alfa was eval-
uated in 17 children with FD in studies TKT023 and
TKT029, conducted over 4 years [3]. Agalsidase alfa was
generally well tolerated, and improvements were ob-
served in levels of urine and plasma Gb3 concentration,
pain severity, and heart rate variability (HRV), while esti-
mated glomerular filtration rate (eGFR) and left ven-
tricular mass indexed to height (LVMI) remained stable.
This study reports on the long-term (6.5 year), open-
label, follow-up of patients who qualified for and opted
to transition from study TKT023 to an extension trial
(TKT029). The objective of extension study TKT029
was to evaluate the safety and efficacy of agalsidase alfa
in pediatric patients with FD treated for up to 7 cumula-
tive years.
Methods
Study design, patient selection, and treatment
This open-label, multicenter extension study (TKT029;
June 10, 2004–June 15, 2011; ClinicalTrials.gov identi-
fier NCT00084084) was designed for pediatric FD pa-
tients (7–17 years of age at study enrollment) who had
received 6 months of 0.2 mg/kg agalsidase alfa in study
TKT023 (August 12, 2002–October 20, 2004) and were
within 30 (±7) days of study completion [3]. Together,
studies TKT023 (0.5 years) and TKT029 (6.5 years)
comprised patients treated for up to 7 years with agal-
sidase alfa. Study TKT029 was divided into two phases:
before (phase 1) and after (phase 2) a change in the
agalsidase alfa manufacturing process [3]. Patients
were included in this report only if they participated in
both phases (transition safety population [TSP]). Phase
2 began ~197 to 223 (mean, 210) weeks after phase 1
baseline agalsidase alfa treatment.
Patients were included if they were determined to be
of adequate general health, without potential safety issues
or medical contraindications, and had written informedconsent provided by a parent or legal guardian. Patients
were excluded if they or their legal guardian were deemed
unable to understand the study requirements and poten-
tial outcomes, or if they were determined by the local in-
vestigator as unlikely to follow the study protocol. In both
studies TKT023 and TKT029, patients received 0.2 mg/kg
body weight of agalsidase alfa every other week, with each
intravenous infusion delivered over a 40-minute period.
Safety and efficacy endpoints
The primary study TKT029 endpoints were safety and
tolerability of agalsidase alfa and its effect on HRV. Sec-
ondary objectives were to determine the pharmacokin-
etics of agalsidase alfa at baseline and after treatment
initiation, as well as exploratory measurements of renal
function (i.e., eGFR), LVMI, and other clinical and patient-
reported outcomes (e.g., plasma and urine Gb3, pain,
health-related quality of life [HRQoL]). As a post hoc ana-
lysis, urine protein: creatinine ratios were evaluated.
Safety assessments
Adverse events (AEs) were characterized by severity, po-
tential relationship to study drug and/or infusion, and
whether they were classifiable as a serious AE (SAE; an
AE that resulted in death, was life-threatening, caused
new or prolonged hospitalization, led to persistent dis-
ability or congenital abnormality, or was considered an
SAE by the treating investigator). Additional safety moni-
toring included clinical laboratory parameters, vital signs,
physical and neurologic examinations, 12-lead electrocar-
diograms, and potential anti-agalsidase alfa antibody activ-
ity evaluated from blood samples screened with an
enzyme-linked immunosorbent assay and confirmed by
a titration assay. Antibody-positive samples were iso-
typed (immunoglobulin [Ig] G, IgA, IgM, or IgE) and
tested for agalsidase alfa neutralizing activity using an
in vitro assay [4].
Efficacy and pharmacodynamic assessments
Cardiac function and structure were assessed through
HRV and LVMI, respectively. HRV was assessed via 2-
hour Holter monitoring. The time-domain HRV parame-
ters assessed in this study were SDNN (standard deviation
[SD] of all filtered RR intervals of the length of the ana-
lysis), r-MSSD (square root of the sum of squares of differ-
ences between adjacent filtered RR intervals over the
length of the analysis), and pNN50 (percentage of differ-
ences between adjacent filtered RR intervals that are
greater than 50 msec for the whole analysis). SDNN was
used as an overall index of HRV, as it encompasses both
long- (sympathetic) and short-term (parasympathetic)
variability and thus reflects the overall autonomic nervous
system activity in the heart. Both r-MSSD and pNN50 de-
scribe short-term variability and thus reflect primarily
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in parasympathetic stimulation of the heart has been
reported in male pediatric patients with FD [5]. In
addition, heart rate was obtained from 12-lead electro-
cardiogram measurements. Echocardiogram and the
Devereux equations were used to calculate LVMI [6].
LVMI baseline for study TKT029 was week 25/26 of
TKT023 (i.e., prior to the first dose of study drug in
TKT029, but after the patients had received treatment
in TKT023).
Renal function was evaluated through eGFR. The
Counahan-Barratt equation was used to calculate eGFR
for patients younger than 18 years of age, using height
and serum creatinine [7]. For patients who aged to
18 years and over during the study, the Modification of
Diet in Renal Disease (MDRD) equation was utilized in-
stead, which factored-in serum creatinine, age, race,
and gender [8]. To assess the impact of the equation
change at the age of 18 years on the eGFR values, sensi-
tivity analyses were performed using continued eGFR
calculated from the Counahan-Barratt equation even
after patients turned 18 years old, or the Chronic
Kidney Disease Epidemiology Collaboration equation
once patients turned 18 years old. As a post hoc ana-
lysis, 8-hour urine collection was used to estimate urine
protein level and proteinuria (defined as urine protein:
creatinine ratio ≥0.2).
Plasma and urine Gb3 were measured at 8-week inter-
vals in study TKT023 and every 6 months in study
TKT029, using a high-performance liquid chromatog-
raphy assay [9]. Other measurements included the Brief
Pain Inventory (severity and interference of pain) [10],Figure 1 Timeline and flow of patients in the TKT023 core trial and T
enrolled in TKT029. Screening values from TKT023 week 25/26 were used a
and after a change in the agalsidase alfa manufacturing process. Patients w
after phase 1 baseline agalsidase alfa treatment. Only patients who particip
for this report. EOW, every other week; agalα, agalsidase alfa; RB, roller bottHealth Utility Index Mark 2 and 3 (HUI; HRQoL) [11,12],
and Child Health Questionnaire (CHQ; HRQoL) [13].
Statistical analysis
The analyses of data are descriptive in nature and no
formal inferential statistical tests were performed. For
variables following a continuous distribution, tabular sum-
maries consist of descriptive statistics (e.g., means, SDs,
medians, minimums, and maximums) and observed and
change from baseline values are presented. For categorical
and ordinal variables, tabular summaries consist of the
number and percentage. For the clinical outcome end-
points (eGFR, plasma and urine sediment Gb3, LVMI, and
HRV), the percentage change from baseline for these pa-
rameters were additionally calculated. As post hoc ana-
lyses, annualized rate of change (slopes) were estimated
for LVMI, eGFR, and urine protein:creatinine ratio based
on the random coefficient model using time as a regressor
to fit each patient’s data; then, the slopes were estimated
by averaging the rate of change across all patients ana-
lyzed. This analysis took into account repeated measure-
ments over time and included data from studies TKT023
and TKT029 (phases 1 and 2).
Results
Patient disposition and demographic characteristics
Eleven of 17 patients transitioned from study phase 1
to phase 2 (i.e., the TSP); one patient was lost to
follow-up in phase 1, four patients were transitioned
first to compassionate-use agalsidase alfa and then to
commercial therapy, and one patient elected to not
continue with additional treatment (Figure 1). Phase 1KT029 extension study. Seventeen patients who completed TKT023
s TKT029 baseline values. TKT029 was divided into two phases, before
ere transitioned to phase 2 treatment ~197 to 223 (mean, 210) weeks
ated in both phases (the transition safety population) were analyzed
le; AF, animal free.
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(8.6–17.3) years (10 [90.9%] males, one female [9.1%],
nine [81.8%] White). Phase 2 began approximately
4 years after phase 1 baseline; thus, some patients aged
past 18 years during the study. One patient failed to
attend scheduled clinic visits and was withdrawn from
the study. Patients in the TSP had mean ± SD duration
of agalsidase alfa treatment of 6.5 ± 0.6 years for a total
of 71.9 patient-years of agalsidase alfa exposure.
Safety profile
The safety profile of 17 patients during phase 1 was de-
scribed previously [3]. At the end of phase 2, all 11 TSP
patients experienced at least one treatment-emergent
AE; the majority of these AEs were mild (phase 1: 0;
phase 2: 3 [27.3%]) or moderate (phase 1: 5 [45.5%];
phase 2: 6 [54.5%]) in intensity (Table 1). Compared with
phase 2, most AEs occurred at a higher incidence inTable 1 Summary of treatment-emergent AEs in the TSP
Patients who experienced:
Phas
≥1 AE 11 (1
≥1 mild AE 0
≥1 moderate AE 5 (45
≥1 severe or life-threatening AE 6 (54
Most common AEs (≥50% of the TSP overall)
Cough 9 (81
Pyrexia 8 (72
Abdominal pain 7 (63
Pain in extremity 8 (72
Chest pain 6 (54
Headache 7 (63
Neuralgia 7 (63
Abdominal pain upper 5 (45
Diarrhea 3 (27
Dyspnea 3 (27
Nasal congestion 6 (54
Nasopharyngitis 3 (27
Vomiting 3 (27
≥1 drug-related AE 8 (72
≥1 infusion-related AE 5 (45
≥1 SAE 1 (9.1
≥1 drug-related SAE 0
Discontinuation due to an AE 0
Death 0
aHighest AE severity was counted at the patient level and the three patients who h
(i.e., moderate, severe, or life-threatening) and are thus classified in a higher severity ca
AE, adverse event; SAE, serious adverse event; TSP, transition study population.phase 1 wherein the duration of agalsidase alfa expos-
ure was longer. Moreover, fewer patients experienced
drug-related, infusion-related, and severe/life-threatening
AEs during phase 2. Eight SAEs arose in two patients
(patient 1: life-threatening road traffic accident and
associated life-threatening traumatic liver injury, facial
bones fracture, and renal injury, one mild and one severe
cerebrovascular accident, and moderate positional vertigo;
patient 2: moderate pectus excavatum requiring surgery),
none of which were deemed drug-related. No study
discontinuations due to AEs occurred and there were
no deaths.
Three patients tested anti-agalsidase antibody posi-
tive. One patient was persistently IgG positive with
agalsidase alfa neutralizing activity starting at week 55
(of phase 1). Another two patients tested transiently for
antibodies (one patient for IgM; one patient for both
IgA and IgM), but without neutralizing activity. None ofTSP, N =11
n (%)
e 1 Phase 2 Overall
00) 11 (100) 11 (100)
3a (27.3) 0a
.5) 6 (54.5) 5 (45.5)
.5) 2 (18.2) 6 (54.5)
.8) 3 (27.3) 10 (90.9)
.7) 3 (27.3) 9 (81.8)
.6) 2 (18.2) 8 (72.7)
.7) 4 (36.4) 8 (72.7)
.5) 3 (27.3) 7 (63.6)
.6) 4 (36.4) 7 (63.6)
.6) 0 7 (63.6)
.5) 2 (18.2) 6 (54.5)
.3) 5 (45.5) 6 (54.5)
.3) 3 (27.3) 6 (54.5)
.5) 2 (18.2) 6 (54.5)
.3) 4 (36.4) 6 (54.5)
.3) 3 (27.3) 6 (54.5)
.7) 2 (18.2) 8 (72.7)
.5) 2 (18.2) 6 (54.5)




ad “mild” events in phase 2 also had a higher severity event in phase 1
tegory in the “Overall” phases (i.e., three mild AEs in phase 2, but none overall).
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dence of infusion-related AEs. No evidence indicated
any potential negative effect based on evaluation of vital
signs, neurologic or physical examinations, and clinical
laboratory test results.
Clinical effects of agalsidase alfa
Baseline mean (SD) SDNN was 91.96 (33.21) msec at
the beginning of phase 1 (measured at study TKT023
week 25/26). Analysis of SDNN showed that the only
negative change from baseline occurred at phase
2 week 13 (mean change of −2.99 msec from phase 2
baseline). All other weeks exhibited consistent mean
HRV increases relative to baseline at all time points,
with an overall change from phase 1 baseline value of
+53.56 msec at the final assessment (Figure 2). Mean
SDNN continued an upward trend throughout phase 2
(mean increase of 34.13 msec at the final assessment).
Evaluations of r-MSSD and pNN50 showed similar
trends for improved HRV over time. At phase 1 baseline,
the mean (SD) r-MSSD and pNN50 values were 45.72
(21.57) msec and 16.58% (13.31%), respectively. Mean
(SD) r-MSSD increased from 45.72 (21.57) msec (n =11)
at phase 1 baseline to 59.88 (39.80) msec (n =9) at week
185. Mean (SD) pNN50 increased from 16.58% (13.31%)
(n =11) at phase 1 baseline to 24.11% (22.51%) (n =9) at
week 185. Insufficient data were available to assess r-
MSSD and pNN50 during study phase 2.
For all patients, baseline LVMI measurements (mea-
sured at study TKT023 week 25/26) were within normal
range (upper limit of normal range: males =51 g/m2.7, fe-
males =48 g/m2.7), with baseline values ranging from
22.7 to 42.3 (mean ± SD phase 1 baseline 30.66 ± 5.96)









































Figure 2 Change from baseline in heart rate variability (mean ± SD SD
2-hour Holter monitoring. Baseline mean ± SD SDNN was 91.96 ± 33.21 mse
Phase 2 began ~197–223 (mean 210) weeks after phase 1 baseline. Agalα, ag
deviation of all filtered RR intervals for the length of the analysis.baseline (mean change −3.25 g/m2.7 at week 185 in
phase 1, which was used instead of the last phase 1
study visit at week 211 that only included three
patients) and LVMI continued to decrease through phase
2 (except week 104). Despite LVMI fluctuations observed
in individual patients, levels remained below left ventricu-
lar hypertrophy criteria throughout the study.
Mean (SD) phase 1 baseline eGFR was 123.29 (16.00)
mL/min/1.73 m2. Most individuals showed relatively
stable eGFR over time, although a reduction in mean
values was observed in the last three phase 2 visits
(Figure 4). For some patients, eGFR fluctuated over
time, although no consistent trends were detected sug-
gesting clinical deterioration, so these fluctuations
were attributed to random variability. One male pa-
tient (004–0004; Figure 4a) exhibited eGFR values that
declined to 73 mL/min/1.73 m2 by end of phase 2.
This patient enrolled in study HGT-REP-059 (clinical-
trials.gov identifier NCT01031173) and experienced an
eGFR increase during that study for a final level of
110 mL/min/1.73 m2, suggesting the eGFR decline was
transient. In addition, protein:creatinine ratio (evalu-
ated from available 8-hour urine samples) remained
relatively stable over the course of treatment (annual-
ized slope: +0.02 [95% confidence interval (CI): 0.00,
0.03]). Eight of 11 patients entered into proteinuria
range (protein:creatinine ratio ≥0.2) during the course
of treatment for one (n =4), two (n =2), or three as-
sessments (n =2); none had proteinuria for more than
three assessments, nor during their final visit.
Plasma Gb3 levels remained below phase 1 baseline
(mean ± SD, 3.61 ± 1.60 nmol/mL; measured at study
TKT023 week 25/26) for most patients throughout the
study (annualized slope −0.01 nmol/mL [95% CI: −0.14,59 185 211 0 13 26 52 78 104 130
alα infusion of each phase
n = 10n = 10
n = 10
n = 11







NN) by visit in the transition safety population. HRV assessed by
c at the beginning of phase 1 (measured at study TKT023 week 25/26).



























(95% CI: –1.33, 0.38)
ULN (males) = 51 g/m2.7






























Weeks from first agalα infusion of each phase
Weeks from first agalα infusion of each phase
b
Figure 3 Left ventricular mass indexed to height (LVMI; g/m2.7) over time in the transition safety population. (a) Individual patients and
(b) mean (± SD) change from baseline; the dotted line represents the annualized slope. Baseline mean ± SD LVMI values at the beginning of
phase 1 were 30.66 ± 5.96 g/m2.7 (measured at study TKT023 week 25/26). Agalα, agalsidase alfa; CI, confidence interval; LVMI, left ventricular mass
index; SD, standard deviation; ULN, upper limit of normal.
Schiffmann et al. Orphanet Journal of Rare Diseases 2014, 9:169 Page 6 of 10
http://www.ojrd.com/content/9/1/1690.12]; Figure 5a). Reductions in plasma Gb3 were main-
tained in patients with moderately and more severely
elevated baseline plasma Gb3, except for one patient. In
patients with high levels of Gb3 at baseline, reductions
were seen throughout phases 1 and 2 and, despite tran-
sient fluctuations, were maintained at last visit. The ob-
served fluctuations in plasma Gb3 were expected based
on the biologic variability inherent to this parameter.
For patients with normal Gb3 levels at baseline, these
levels remained normal throughout the study. Similar
to the plasma Gb3 profile, levels of urine Gb3 excretion
fluctuated over time, but decreased from the phase 1 base-
line value (mean ± SD: 538.09 ± 681.27 nmol/g) with an
annualized slope of −50.02 nmol/g (95% CI: −152.41,
52.37; Figure 5b). Urine Gb3 excretion remained generally
stable, but for some patients, urine Gb3 fluctuated over
time. However, no trends were found that suggested clin-
ical deterioration.
For other parameters evaluated, no notable changes
were detected in any of the HUI items and proxy
assessed CHQ scale and summary scores. While a sig-
nificant reduction in pain severity was seen during
TKT023, the reduced pain scores were subsequently
maintained and little change was observed in BriefPain Inventory short form items from baseline to the
end of TKT029.
Discussion
This study represents the longest assessment of ERT for
the treatment of children with FD in a clinical trial set-
ting. Agalsidase alfa was generally well tolerated over
approximately 7 years of cumulative treatment with
most treatment-emergent AEs being mild or moderate
in intensity. No treatment-related SAEs were detected;
no patients discontinued study participation due to AEs
and there were no deaths. The incidence of drug-
related and infusion-related AEs decreased over time.
No other safety concerns were identified, based on
other assessed clinical parameters. Anti-agalsidase alfa
antibody formation was low (3/11, 27.3% of the TSP)
and with no apparent impact on clinical outcomes. No
new safety concerns were identified from all assessed
clinical parameters.
HRV improvements originally observed in study TKT023
appeared to be maintained in this extension trial, with an
upward trend in SDNN (milliseconds) during phase 2
(SDNN HRV at baseline phase 1: 91.96 msec, by week
















































































Weeks from first agalα infusion of each phase
Weeks from first agalα infusion of each phase
Annualized slope +0.22/yr 
(95% CI: –2.84, 3.28)
b
Figure 4 Estimated glomerular filtration rate (eGFR; mL/min/1.73 m2) over time in the transition safety population. (a) Individual
patients and (b) mean (± SD) change from baseline; the dotted line represents the annualized slope. Baseline mean ± SD eGFR values at the
beginning of phase 1 were 123.29 ± 16.00 mL/min/1.73 m2 (measured at study TKT023 week 25/26). Agalα, agalsidase alfa; CI, confidence interval;
eGFR, estimated glomerular filtration rate; SD, standard deviation; yr, year.
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in children increases with age (boys: 57 ± 62 msec [aged
3.4 ± 1.6 years] to 187 ± 38 msec [aged 16.4 ± 0.8 years];
girls: 87 ± 16 msec [aged 2.7 ± 1.8 years] to 201 ±
24 msec [aged 17.4 ± 1.7 years]) [14]. Several patients
experienced a reduction in heart rate to below 60 beats
per minute based on the 12-lead electrocardiogram,
suggestive of bradycardia (Additional file 1: Figure S1).
However, bradycardia was not specifically tested for as
an endpoint in this study, and no investigators reported
an instance of bradycardia as a treatment-emergent AE.
Future research would be required to evaluate whether
bradycardia is potentially a bradyarrhythmia associated
with FD [15,16].
In addition, LVMI remained generally stable and
none of the patients reached the adult criteria for left
ventricular hypertrophy. Although no studies have been
published evaluating annualized slope in LVMI in a
population comprising only children with FD, a cross-
sectional echocardiographic study of FD in untreated
patients (including adults and children) found that males
without LVH had a mean (± standard error of the mean)
annualized LVMI change of +4.07 ± 1.03 g/m2.7 (n =39)
and females had 2.31 ± 0.81 g/m2.7 (n =39) [17]. In pa-
tients aged <20 years, males experienced a medianannualized rate of change of +2.00 g/m2.7 (n =5) and fe-
males changed by +1.36 g/m2.7 (n =9). In study TKT029
(pediatric, predominantly male patients), LVMI annualized
slope was −0.48 (95% CI: −1.33, 0.38) g/m2.7. The level of
LVMI directly correlates with increasing age [17], so fu-
ture research would be required for a comparative analysis
of current results and the natural history of LVMI in chil-
dren with FD.
Similarly, renal function was generally stable over the
course of the study for most of the patients, albeit with
considerable variability during follow-up (e.g., some pe-
riods of hyperfiltration with an eGFR >130 mL/min/
1.73 m2 were observed). Although we are not aware of
a study evaluating annualized slope change in eGFR in
children with FD, eGFR slopes were assessed in a
retrospective chart review study of natural history in a
mixed population of adults and children (median
[range] age 41.0 years [5.0–77.1]) [18]. In the latter
study, males and females (who did not progress to end-
stage renal disease) experienced annualized mean eGFR
changes of −2.93 mL/min/1.73 m2 (n =128) and −1.02 mL/
min/1.73 m2 (n =51), respectively. The overall annualized
slope in study TKT029 showed a small upward trend
of +0.22 (95% CI: −2.84, 3.28) mL/min/1.73 m2 through





















































































(95% CI: –0.14, 0.12)
b
Figure 5 Mean ± SD change over time in plasma/urine Gb3 in the transition safety population. (a) Plasma Gb3 (nmol/g creatinine) and
(b) urine Gb3 (nmol/mL); the dotted lines represent the annualized slope. Baseline mean ± SD plasma Gb3 and urine Gb3 values at the beginning
of phase 1 were 3.61 ± 1.60 nmol/mL and 538.09 ± 681.27 nmol/g creatinine, respectively (both measured at study TKT023 week 25/26). Agalα,
agalsidase alfa; CI, confidence interval; Gb3, globotriaosylceramide; SD, standard deviation; yr, year.
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research would be required to determine if early initiation
of agalsidase alfa therapy during childhood could have pre-
ventive or ameliorating effects on decline in eGFR with
aging. The annualized slope of protein:creatinine ratio was
relatively stable (+0.02 [95% CI: 0.00, 0.03]), no patients en-
tered the proteinuria range (protein:creatinine ratio ≥0.2)
during treatment for more than three assessments, and
none had proteinuria during their final visit.
Both plasma and urine Gb3 showed decreases from
the baseline to the end of study TKT023, and these re-
ductions in Gb3 were essentially maintained in study
TKT029. The presence of neutralizing anti-agalsidase
alfa antibodies has been reported to have a negative ef-
fect on the reduction of urine Gb3 levels [19]. Here, only
one patient developed anti-agalsidase alfa IgG antibodies
with neutralizing activity. This patient had a moderately
increased level of urine Gb3 at baseline that fluctuated
above baseline throughout the study and was slightly
higher than baseline level at study completion. However,
another patient who was anti-agalsidase alfa antibody
negative with a moderately elevated level of urine Gb3 atbaseline, showed fluctuations at various time points, and
at study completion had a level similar to that at base-
line. It is thus not possible to draw any definitive conclu-
sions regarding the effect of neutralizing anti-agalsidase
alfa antibodies on urine Gb3 levels in our study.
This study has several limitations. First, TKT029 was
not a comparative or placebo-controlled clinical trial,
which limits the ability to draw conclusions relative to a
control population. In addition, the number of patients
in the TSP was small, limiting the power to detect
within-patient effects. Because of the lack of a compara-
tor group and low patient number, conducting inferen-
tial statistical analyses was impractical, so the results are
descriptive only. Furthermore, some patients had tran-
sitioned from childhood to adolescence and adulthood.
The inclusion of adult patients made evaluation of certain
endpoints challenging, as different validated equations
needed to be used (e.g., Counahan-Barratt equation for
pediatric eGFR versus MDRD for adult eGFR). Never-
theless, we made every effort to conduct sensitivity ana-
lyses to verify the results. Urine protein data were
assessed from 8-hour urine collection; the accuracy of
Schiffmann et al. Orphanet Journal of Rare Diseases 2014, 9:169 Page 9 of 10
http://www.ojrd.com/content/9/1/169the estimates may be limited because of inconsistent
reporting by individual laboratories as well as missing
values. Finally, the prognostic value of HRV in pediatric
patients has not been well established, although one
study found a reduction in HRV in boys, but not girls
[5]. Future studies will be necessary to evaluate protein-
uria effects in detail.Conclusions
Overall, agalsidase alfa was well tolerated and demonstrated
a stabilizing clinical effect. Thus, agalsidase alfa may be a
useful clinical therapeutic option for the long-term treat-
ment initiated during childhood in patients with FD.Additional file
Additional file 1: Figure S1. Estimated mean (± SD) change from
baseline heart rate in the transition safety population. Heart rate (HR) in
beats per minute (bpm) was estimated by 12-lead electrocardiography
(ECG). Baseline mean ± SD HR at the beginning of phase 1 was 77.8 ±
14.6 bpm (measured at study TKT029 baseline). SD, standard deviation.Abbreviations
AE: Adverse event; CI: Confidence interval; eGFR: Estimated glomerular filtration
rate; ERT: Enzyme replacement therapy; FD: Fabry Disease;
Gb3: Globotriaosylceramide; HRQoL: Health-related quality of life; HRV: Heart rate
variability; Ig: Immunoglobulin; LVMI: Left ventricular mass index;
MDRD: Modification of Diet in Renal Disease; pNN50: Percentage of differences
between adjacent filtered RR intervals that are greater than 50 msec for the
whole analysis; r-MSSD: Square root of the sum of squares of differences
between adjacent filtered RR intervals over the length of the analysis;
SD: Standard deviation; SDNN: Standard deviation of all filtered RR intervals for
the length of the analysis; SDNN-i/SDNN: Mean of the SDs of all filtered RR
intervals for all 5-minute segments of the analysis; SDANN-i/SDANN: SD of the
means of all filtered RR intervals for all 5-minute segments of the analysis;
TSP: Transition safety population.
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